Consumer-direct fertility fintech pairing IVF/egg-freezing loans with concierge care navigation, entered at a $15M pre-money in the depths of pandemic-forced clinic shutdowns. The wedge is a full-stack financial + care product for the ~70% of US patients whose employers do not cover fertility — underwritten by proprietary loan data on a high-ticket, life-decision purchase that would otherwise be paid out-of-pocket.
Validation at Series A1 entry: founder Claire Tomkins was already a repeat go-to-market operator (ex-SolarCity/Tesla) executing a differentiated cash-pay strategy while competitors (Progyny, Carrot, Kindbody) chased employer channels. StoryHouse participated at a $15M pre-money via T-Bird and Correlation vehicles alongside undisclosed co-investors in what was later publicly announced in May 2021 as the “Series A-1” round Web. Entry point is attractive relative to the $80M pre-money Series B closed in April 2022, only ~23 months later Web.
At May 2020 entry, IVF was still a predominantly cash-pay, out-of-pocket market with only ~30% of US employees having any fertility benefit coverage. Secular tailwinds — delayed childbearing, rising infertility rates, LGBTQ+ family building, and elective egg-freezing — drove structural demand. The US IVF services market alone has since been forecast to grow at ~11.3% CAGR to ~$14B by 2032 Web. Cash-pay financing remains the white space Future Family targets even as employer benefits expand.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Future Family | Direct-to-patient IVF/egg-freezing loans + concierge care navigation; cash-pay wedge for uninsured/underinsured patients | Series A1, $5M on $15M pre (SH entry 2020-05-17) | — |
| Progyny | Employer-channel fertility benefits manager; IPO’d Oct 2019 | Public (PGNY) at time of entry Web | FF reaches the ~70% of employees whose employers don’t offer coverage |
| Carrot Fertility | Reimbursement-model employer benefit for family-building | Series B era; later ~$500M val, $114M+ raised Web | FF underwrites patient loans directly; Carrot passes cost to employer |
| Kindbody | Vertically integrated clinic network + employer benefits | Early growth stage (2020); later $1.8B val March 2023 Web | FF is asset-light financing/software; Kindbody carries clinic capex |
| Prosper Healthcare Lending / LendingClub | Generalist medical lending (not fertility-specific) | Established consumer lenders | FF has fertility-specific underwriting + care team + clinic distribution |
Moat: Category-specific loan underwriting data on IVF/egg-freezing patients, clinic distribution partnerships, and a concierge-care wrapper that competitors in generalist medical lending cannot replicate; a decade later this position was extended into a regulated national IVF insurance product Web.
Digital-health M&A dominated 2025 exits, representing ~95% of exit volume across 2025–1H 2026 Web. Recent fertility-sector comparables include IVI RMA’s acquisition of ART Fertility for $400–450M and PureHealth’s 60% stake in Hellenic Healthcare at $2.3B, both in 2025 Web.
Likely acquirers: employer-benefits incumbents extending into cash-pay (Progyny, Carrot, Maven), health insurers (Cigna/Evernorth, UnitedHealth/Optum), and reinsurers already exposed to the category (Munich Re, an existing investor).
No meeting notes are linked to this Deal record in Airtable. Diligence context has been reconstructed from Airtable Deal/Company/Contacts fields and public-web sources listed below.